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Background: Prior studies have shown that patients with angina symptoms incur substantial healthcare costs due to frequent medical visits, 
hospitalizations and revascularization procedures. This study assesses the impact of ranolazine, a novel antianginal treatment, on healthcare costs.
Methods: A retrospective case-control analysis was conducted using medical and treatment information of angina patients retrieved from a 
national health insurance database. Patients with angina ICD-9 diagnosis codes and antianginal prescriptions between July 2005 and February 
2008 were identified. Patients who added or switched to ranolazine, nitrates, beta-blockers (BB) or calcium channel blockers (CCB) were assumed 
to have angina symptoms and were assigned to the corresponding treatment group: ranolazine, nitrate, or BB/CCB. For each group, frequency 
of hospitalizations, revascularization procedures (PCI or CABG) and healthcare costs were evaluated for a period of 6 months post antianginal 
medication change. Risk of revascularization and healthcare costs for each group were adjusted for differences in demographic, comorbidity and 
prior revascularization using logistic regression and generalized linear modeling.
Results: Ranolazine (n=881), nitrate (n=1,788) and BB/CCB (n=1,876) patients had similar demographic characteristics, comorbidities and prior 
revascularization rates (25.0%, 26.5%, 25.2%, respectively). Six-month post antianginal medication change, ranolazine patients had significantly 
lower rates of PCI than the nitrate and BB/CCB groups (8.3% vs 14.1%, 11.9%, p<0.01), CABG (2.0% vs 6.5%, 4.0%, p<0.01) and hospitalizations 
(27.4% vs 33.2%, 33.8%, p<0.01). Odds of revascularization in the ranolazine group were 58% lower than the nitrate group (OR 0.42 [0.33-0.55]) 
and 40% lower than the BB/CCB group (OR 0.60 [0.46-0.77]). Adjusted healthcare costs were 21% to 23% less in the ranolazine group ($13,961) 
compared to nitrate ($18,166; p<0.01) and BB/CCB ($17,612; p<0.01) groups.
Conclusion: Use of ranolazine in patients with angina was associated with lower rates of hospitalizations, PCI, CABG and lower healthcare costs in 
the first 6 months following initiation of the drug.
